Literature DB >> 22722631

GABAB-ergic motor cortex dysfunction in SSADH deficiency.

Janine Reis1, Leonardo G Cohen, Phillip L Pearl, Brita Fritsch, Nikolai H Jung, Irene Dustin, William H Theodore.   

Abstract

OBJECTIVE: Succinic semialdehyde dehydrogenase (SSADH) deficiency is a rare autosomal recessive disorder of GABA degradation leading to elevations in brain GABA and γ-hydroxybutyric acid (GHB). The effect of chronically elevated GABA and GHB on cortical excitability is unknown. We hypothesized that use-dependent downregulation of GABA receptor expression would promote cortical disinhibition rather than inhibition, predominantly via presynaptic GABAergic mechanisms.
METHODS: We quantified the magnitude of excitation and inhibition in primary motor cortex (M1) in patients with SSADH deficiency, their parents (obligate heterozygotes), age-matched healthy young controls, and healthy adults using single and paired pulse transcranial magnetic stimulation (TMS).
RESULTS: Long interval intracortical inhibition was significantly reduced and the cortical silent period was significantly shortened in patients with SSADH deficiency compared to heterozygous parents and control groups.
CONCLUSIONS: Since long interval intracortical inhibition and cortical silent period are thought to reflect GABA(B) receptor-mediated inhibitory circuits, our results point to a particularly GABA(B)-ergic motor cortex dysfunction in patients with SSADH deficiency. This human phenotype is consistent with the proposed mechanism of use-dependent downregulation of postsynaptic GABA(B) receptors in SSADH deficiency animal models. Additionally, the results suggest autoinhibition of GABAergic neurons. This first demonstration of altered GABA(B)-ergic function in patients with SSADH deficiency may help to explain clinical features of the disease, and suggest pathophysiologic mechanisms in other neurotransmitter-related disorders.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22722631      PMCID: PMC3385496          DOI: 10.1212/WNL.0b013e31825dcf71

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  40 in total

1.  The cortical silent period: intrinsic variability and relation to the waveform of the transcranial magnetic stimulation pulse.

Authors:  M Orth; J C Rothwell
Journal:  Clin Neurophysiol       Date:  2004-05       Impact factor: 3.708

Review 2.  Transcranial magnetic stimulation in children.

Authors:  Marjorie A Garvey; Donald L Gilbert
Journal:  Eur J Paediatr Neurol       Date:  2004       Impact factor: 3.140

3.  Plasticity of postsynaptic, but not presynaptic, GABAB receptors in SSADH deficient mice.

Authors:  Irina Vardya; Kim R Drasbek; K Michael Gibson; Kimmo Jensen
Journal:  Exp Neurol       Date:  2010-06-04       Impact factor: 5.330

4.  Gamma-hydroxybutyrate is a weak agonist at recombinant GABA(B) receptors.

Authors:  K Lingenhoehl; R Brom; J Heid; P Beck; W Froestl; K Kaupmann; B Bettler; J Mosbacher
Journal:  Neuropharmacology       Date:  1999-11       Impact factor: 5.250

Review 5.  Excitatory actions of gaba during development: the nature of the nurture.

Authors:  Yehezkel Ben-Ari
Journal:  Nat Rev Neurosci       Date:  2002-09       Impact factor: 34.870

Review 6.  Pharmacology of TMS.

Authors:  Ulf Ziemann
Journal:  Suppl Clin Neurophysiol       Date:  2003

Review 7.  Succinic semialdehyde dehydrogenase deficiency in children and adults.

Authors:  Phillip L Pearl; Edward J Novotny; Maria T Acosta; Cornelis Jakobs; K Michael Gibson
Journal:  Ann Neurol       Date:  2003       Impact factor: 10.422

8.  4-Hydroxy-trans-2-nonenoic acid is a gamma-hydroxybutyrate receptor ligand in the cerebral cortex and hippocampus.

Authors:  Tonya C Murphy; Claire Poppe; James E Porter; Thomas J Montine; Matthew J Picklo
Journal:  J Neurochem       Date:  2004-06       Impact factor: 5.372

9.  Topiramate selectively decreases intracortical excitability in human motor cortex.

Authors:  Janine Reis; Frithjof Tergau; Hajo M Hamer; Hans-Helge Müller; Susanne Knake; Brita Fritsch; Wolfgang H Oertel; Felix Rosenow
Journal:  Epilepsia       Date:  2002-10       Impact factor: 5.864

10.  Mutational spectrum of the succinate semialdehyde dehydrogenase (ALDH5A1) gene and functional analysis of 27 novel disease-causing mutations in patients with SSADH deficiency.

Authors:  Shinjiro Akaboshi; Boris M Hogema; Andrea Novelletto; Patrizia Malaspina; Gajja S Salomons; George D Maropoulos; Cornelis Jakobs; Markus Grompe; K Michael Gibson
Journal:  Hum Mutat       Date:  2003-12       Impact factor: 4.878

View more
  16 in total

Review 1.  Thirty years beyond discovery--clinical trials in succinic semialdehyde dehydrogenase deficiency, a disorder of GABA metabolism.

Authors:  Kara R Vogel; Phillip L Pearl; William H Theodore; Robert C McCarter; Cornelis Jakobs; K Michael Gibson
Journal:  J Inherit Metab Dis       Date:  2012-06-28       Impact factor: 4.982

2.  Gamma-Hydroxybutyrate (GHB) Content in Hair Samples Correlates Negatively with Age in Succinic Semialdehyde Dehydrogenase Deficiency.

Authors:  S S Johansen; X Wang; D Sejer Pedersen; P L Pearl; J-B Roullet; G R Ainslie; K R Vogel; K M Gibson
Journal:  JIMD Rep       Date:  2017-02-18

Review 3.  Safety of Transcranial Magnetic Stimulation in Children: A Systematic Review of the Literature.

Authors:  Corey H Allen; Benzi M Kluger; Isabelle Buard
Journal:  Pediatr Neurol       Date:  2017-01-04       Impact factor: 3.372

Review 4.  Inherited disorders of gamma-aminobutyric acid metabolism and advances in ALDH5A1 mutation identification.

Authors:  Phillip L Pearl; Mahsa Parviz; Kara Vogel; John Schreiber; William H Theodore; K Michael Gibson
Journal:  Dev Med Child Neurol       Date:  2014-12-29       Impact factor: 5.449

5.  Disorders of GABA metabolism: SSADH and GABA-transaminase deficiencies.

Authors:  Mahsa Parviz; Kara Vogel; K Michael Gibson; Phillip L Pearl
Journal:  J Pediatr Epilepsy       Date:  2014-11-25

6.  Biomarkers in a Taurine Trial for Succinic Semialdehyde Dehydrogenase Deficiency.

Authors:  John M Schreiber; Phillip L Pearl; Irene Dustin; Edythe Wiggs; Emily Barrios; Eric M Wassermann; K Michael Gibson; William H Theodore
Journal:  JIMD Rep       Date:  2016-06-24

7.  Correlation of blood biomarkers with age informs pathomechanisms in succinic semialdehyde dehydrogenase deficiency (SSADHD), a disorder of GABA metabolism.

Authors:  E E Jansen; K R Vogel; G S Salomons; P L Pearl; J-B Roullet; K M Gibson
Journal:  J Inherit Metab Dis       Date:  2016-09-29       Impact factor: 4.982

8.  Allopregnanolone Treatment Improves Plasma Metabolomic Profile Associated with GABA Metabolism in Fragile X-Associated Tremor/Ataxia Syndrome: a Pilot Study.

Authors:  Eleonora Napoli; Andrea Schneider; Jun Yi Wang; Aditi Trivedi; Nika Roa Carrillo; Flora Tassone; Michael Rogawski; Randi J Hagerman; Cecilia Giulivi
Journal:  Mol Neurobiol       Date:  2018-09-05       Impact factor: 5.590

9.  mTOR inhibitors rescue premature lethality and attenuate dysregulation of GABAergic/glutamatergic transcription in murine succinate semialdehyde dehydrogenase deficiency (SSADHD), a disorder of GABA metabolism.

Authors:  Kara R Vogel; Garrett R Ainslie; K Michael Gibson
Journal:  J Inherit Metab Dis       Date:  2016-08-12       Impact factor: 4.982

Review 10.  Succinic semialdehyde dehydrogenase deficiency (SSADHD): Pathophysiological complexity and multifactorial trait associations in a rare monogenic disorder of GABA metabolism.

Authors:  P Malaspina; J-B Roullet; P L Pearl; G R Ainslie; K R Vogel; K M Gibson
Journal:  Neurochem Int       Date:  2016-06-14       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.